Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma
Open Access
- 10 October 2007
- journal article
- research article
- Published by Hindawi Limited in International Journal of Clinical Practice
- Vol. 61 (11), 1874-1883
- https://doi.org/10.1111/j.1742-1241.2007.01574.x
Abstract
Budesonide/formoterol is an effective treatment for both asthma and chronic obstructive pulmonary disease. This study compared the efficacy and safety of a novel hydrofluoroalkane (HFA) pressurised metered-dose inhaler (pMDI) formulation of budesonide/formoterol with that of budesonide pMDI and budesonide/formoterol dry-powder inhaler (DPI; Turbuhaler®). This was a 12-week, multinational, randomised, double-blind, double-dummy study involving patients aged ≥ 12 years with asthma. All patients had a forced expiratory volume in 1 s of 50–90% predicted normal and were inadequately controlled on inhaled corticosteroids (500–1600 mu g/day) alone. Following a 2-week run-in, during which they received their usual medication, patients were randomised (two inhalations twice daily) to budesonide pMDI 200 mu g, budesonide/formoterol DPI 160/4.5 mu g or budesonide/formoterol pMDI 160/4.5 mu g. The primary efficacy end-point was change from baseline in morning peak expiratory flow (PEF). In total, 680 patients were randomised, of whom 668 were included in the primary analysis. Therapeutically equivalent increases in morning PEF were observed with budesonide/formoterol pMDI (29.3 l/min) and budesonide/formoterol DPI (32.0 l/min) (95% confidence interval: −10.4 to 4.9; p = 0.48). The increase in morning PEF with budesonide/formoterol pMDI was significantly higher than with budesonide pMDI (+28.7 l/min; p < 0.001). Similar improvements with budesonide/formoterol pMDI vs. budesonide pMDI were seen for all secondary efficacy end-points. Both combination treatments were similarly well tolerated. Budesonide/formoterol, administered via the HFA pMDI or DPI, is an effective and well-tolerated treatment for adult and adolescent patients with asthma, with both devices being therapeutically equivalent.Keywords
This publication has 35 references indexed in Scilit:
- Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option?European Respiratory Journal, 2005
- Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthmaCurrent Medical Research and Opinion, 2004
- Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthmaCurrent Medical Research and Opinion, 2004
- Budesonide/FormoterolDrugs, 2004
- Pharmacokinetics and systemic activity of fluticasone via Diskus® and pMDI, and of budesonide via Turbuhaler®British Journal of Clinical Pharmacology, 2001
- Advances in Metered Dose Inhaler Technology with the Development of a Chlorofluorocarbon-Free Drug Delivery SystemJournal of Aerosol Medicine, 1999
- Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthmaJournal of Allergy and Clinical Immunology, 1998
- Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potencyEuropean Respiratory Journal, 1997
- Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDIEuropean Respiratory Journal, 1994
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994